Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows From Operating Activities:    
Net loss $ (11,111,547) $ (5,810,230)
Adjustments to reconcile net loss to net cash used in operating activities:    
Bad debt expense 7,000  
Impairment loss on intangible assets 2,626,974  
Impairment loss on property and equipment 49,948  
Impairment loss on goodwill 463,000  
Depreciation and amortization 330,993 304,068
Change in fair value of contingent consideration (613,000)  
Common stock 872,123 516,381
Options 6,598 7,618
Changes in operating assets and liabilities:    
Accounts receivable 1,835,718 1,000,783
Other receivable 507,387  
Prepaid expenses and other current assets 350,132 (155,367)
Accounts payable - suppliers (1,117,112) 115,681
Accounts payable - trade (290,321) (289,215)
Accrued expenses and other current liabilities (1,817,278) (274,667)
Accrued interest   7,025
Deferred revenue 371,919  
Net Cash Used In Operating Activities (7,527,466) (4,577,923)
Cash Flows From Investing Activities:    
Purchase of intangible assets   (1,133,072)
Purchase of property and equipment (16,549) (24,331)
Net Cash Used In Investing Activities (16,549) (1,157,403)
Cash Flows From Financing Activities:    
Proceeds from exercise of warrants [1]   9,787,149
Proceeds from exercise of options   8,361
Repayment of PPP loan (149,843) (68,346)
Repayment of financed director and officer insurance premiums (316,542)  
Payment of deferred offering costs   (27,510)
Net Cash (Used In) Provided By Financing Activities (466,385) 9,699,654
Net (Decrease) Increase In Cash and Cash Equivalents (8,010,400) 3,964,328
Cash and Cash Equivalents - Beginning of the Period 24,907,963 24,782,128
Cash and Cash Equivalents - End of the Period 16,897,563 28,746,456
Cash paid during the period for:    
Interest 4,847 4,588
Non-cash investing and financing activities:    
Surrender and cancellation of common stock (18,683)  
Shares of common stock issued in satisfaction of accrued issuable equity   507,044
Accrual of warrant exercise issuance costs   83,519
Shares issued as partial consideration for intangible asset   532,000
Financing of insurance premiums $ 357,866 $ 362,625
[1] Includes gross proceeds of $10,169,027, less issuance costs of $381,878.